RxDoctor Payments Data

Vijaya Nama, MD

Family Medicine · Mesquite, TXNPI 1306829791

Payments from drug & device makers

$5,699in general payments, 2019–2025

Across 336 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$754
  • Amgen$694
  • Novo Nordisk$634
  • Lilly USA, LLC$544
  • Boehringer Ingelheim$357
  • Amarin Pharma, Inc.$312
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$5,47096%
  • Education$1002%
  • Other$1292%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,699 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$95,822
Medicare patients
141
Services billed
1,264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin157$217,172
OzempicSemaglutide84$171,931
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog71$99,770
MounjaroTirzepatide46$95,324
FarxigaDapagliflozin Propanediol64$87,149
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog61$83,040
Janumet XrSitagliptin Phos/Metformin Hcl57$73,123
EliquisApixaban54$71,680
Synjardy XrEmpagliflozin/Metformin Hcl36$56,228
JanuviaSitagliptin Phosphate34$54,051
ProliaDenosumab29$51,110
SynjardyEmpagliflozin/Metformin Hcl30$49,295
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$47,330
TrulicityDulaglutide17$38,418
LinzessLinaclotide27$34,361

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Synjardy$357$322,696223 claims
Novo NordiskOzempic$634$171,93184 claims
MerckJanumet Xr, Januvia, Janumet$283$155,923119 claims
Lilly USA, LLCMounjaro, Trulicity$544$133,74263 claims
AstraZenecaFarxiga, Breztri Aerosphere$754$118,40890 claims
GSKTrelegy Ellipta, Anoro Ellipta$282$79,57160 claims
PfizerEliquis$158$71,68054 claims
AmgenProlia$694$51,11029 claims
AbbVieLinzess, Synthroid$157$36,92546 claims
NovartisEntresto$50$32,46916 claims
Astellas Pharma US IncMyrbetriq$160$10,87111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Mesquite

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →